Net income · 2017–2025
Bridgebio Pharma net income
−$733M−$190M · FY2025
Bridgebio Pharma (BBIO) reported −$733M in net income for fiscal 2025, −$190M from the year before.
| Fiscal year | Net income | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | −$733M | −$190M | Open → |
| FY20242024-12-31 | −$543M | +$110M | Open → |
| FY20232023-12-31 | −$653M | −$169M | Open → |
| FY20222022-12-31 | −$485M | +$102M | Open → |
| FY20212021-12-31 | −$586M | −$81.0M | Open → |
| FY20202020-12-31 | −$505M | −$217M | Open → |
| FY20192019-12-31 | −$289M | −$119M | Open → |
| FY20182018-12-31 | −$169M | −$126M | Open → |
| FY20172017-12-31 | −$43.8M | — | Open → |
Net income — Net income is profit after tax and all expenses, as reported in the annual filing. Companies reporting a loss are excluded from this ranking.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Net income at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bridgebio Pharma net income |url=https://companiesranked.com/en/company/bridgebio-pharma/net-income |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bridgebio Pharma net income. CompaniesRanked. https://companiesranked.com/en/company/bridgebio-pharma/net-incomeBibTeX
@misc{companiesranked-en-company-bridgebio-pharma-net-income-2026,
author = {{CompaniesRanked}},
title = {{Bridgebio Pharma net income}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bridgebio-pharma/net-income}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.